Antibiotic Resistance: A Mounting Threat of Epidemic Proportions -Dr. Deepti Jaggi-06/12/2012 - 6:00pm

Event Information
Event Topic: 
Antibiotic Resistance: A Mounting Threat of Epidemic Proportions
Event Date: 
06/12/2012 - 6:00pm
Event Location: 
Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Speaker Information
Event Speaker: 
Dr. Deepti Jaggi
Event Speaker Title: 
Co-founder, President and Chief Medical Officer
Event Speaker Company: 
Vivonyx Inc.
Event Speaker Bio: 

Dr. Deepti Jaggi

Dr. Deepti Jaggi is the Co-founder, President and Chief Medical Officer of ca clinical stage biopharmaceutical company focused on creating lifesaving antibiotics. Dr. Jaggi has spent 20 years in the Healthcare & Lifesciences industry and is a co-founder of multiple biotechnology companies including Novakos, a Lifesciences accelerator and Neurokos Inc., a clinical stage neurology company. Her educational background includes a Pharm. D from the University of Southern California and an MBA from Stanford Graduate School of Business.

Dr. Jaggi’s clinical work including at Kaiser Permanente, encompasses various specialties including geriatrics, intensive care, infectious disease, HIV/AIDS, pediatrics, oncology, cardiology and primary care. Her pharmaceutical industry experience includes positions of increasing responsibility at Genentech and J&J where she was responsible for product development, R&D strategy, and portfolio management. Dr. Jaggi has been an invited presenter in Drug Development Advisory meetings including those held at or sponsored by the US FDA & EMEA. She has served on multiple advisory committees including the Alzheimer's Prevention Initiative (API), Dominantly Inherited Alzheimer's Network (DIAN) and at the Stanford Graduate School of Business. She serves on boards of multiple companies and is passionate about mentoring entrepreneurs and scientists interested in biopharmaceutical careers. Dr. Jaggi is also involved with many non-profits including those focused on education and children.

Event Details
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Event Details: 

Alexander Fleming discovered penicillin revolutionizing medical care over 70 years ago. Since then we’ve enjoyed the benefits of antibiotics and their ability to successfully overcome once fatal diseases such as tuberculosis and plague. But alarmingly, antibiotic use has promoted widespread resistance, which is fast reaching epidemic proportions.

Healthcare-associated infections already account for 1.7M infections and 99,000 deaths. Hospital-acquired infections, many resistant to first line antibiotics, cost the U.S. healthcare system an estimated $30B each year. The situation is further worsened by plummeting rates of discovery of new antibiotics. Many large pharmaceutical companies have exited the antibiotic R&D space citing difficulties and costs of developing new antibiotics. In April 2011, IDSA issued a report warning that unless significant measures are taken to increase the pipeline of new antibiotics, people will start to die from common, formerly treatable infections, and medical interventions such as surgery, chemotherapy, organ transplantation and care of premature of infants will become increasingly risky.

Bacteria are smart and evolve efficiently making antibiotics ineffective. Can medical innovation outsmart them? Are there ways to not only overcome, but prevent resistance? A young and exciting San Francisco bay area biopharmaceutical startup, Vivonyx, may have an answer.